Core Insights - Abbott Laboratories (ABT) is expected to report second-quarter 2025 results on July 17, with adjusted earnings per share (EPS) of $1.09 in the last quarter, surpassing the Zacks Consensus Estimate by 1.9% [1] - The Zacks Consensus Estimate for revenues is $11.07 billion, indicating a 6.7% increase year-over-year, while EPS is estimated to rise 9.6% to $1.25 [1][2] Revenue Estimates by Segment - **Diagnostics**: Expected revenue growth impacted by a decline in COVID-19 testing revenues, but anticipated to benefit from high demand across various settings. Estimated revenue increase of 0.1% year-over-year [3][4][6] - **Established Pharmaceuticals (EPD)**: Projected to continue strong performance across multiple regions and therapeutic areas, with a year-over-year revenue increase of 6.1% [7][8] - **Medical Devices**: Anticipated to show significant growth, driven by the Diabetes Care division and continuous glucose monitor (CGM) systems, with a projected revenue increase of 10.9% year-over-year [8][9][13] - **Nutrition**: Expected robust sales from adult nutrition brand Ensure and solid growth in infant formula and toddler brands, with a year-over-year revenue improvement of 4.3% [13] Earnings Estimate Revision - Estimates for Q2 earnings have remained unchanged at $1.25 per share over the past 30 days, indicating stability in expectations [3] Market Position and Growth Drivers - The Medical Devices segment is highlighted as a standout performer, with growth driven by new product approvals and strong demand in various categories, including heart assist devices and structural heart products [10][11][12]